Results 1 to 10 of about 137,000 (307)

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. [PDF]

Nat Med
Rampal RK, Grosicki S, Chraniuk D, Abruzzese E, Bose P, Gerds AT, Vannucchi AM, Palandri F, Lee SE, Gupta V, Lucchesi A, Oh ST, Kuykendall AT, Patriarca A, Álvarez-Larrán A, Mesa R, Kiladjian JJ, Talpaz M, Scandura JM, Lavie D, Harris M, Kays SK, Li Q, Boxhammer R, Brown B, Jegg AM, Harrison CN, Mascarenhas J.   +27 more
europepmc   +2 more sources

Protocol for transcriptomic and epigenomic analysis of JAK inhibitor sensitivity in IFN-γ-primed human macrophages using ATAC-seq and RNA-seq. [PDF]

STAR Protoc
Kwon G, Noh J, Lee J, Kang K, Kang K.
europepmc   +1 more source

Towards New Strategies: Case Report and Review of the Literature-Effective Use of JAK Inhibitor Baricitinib in a 4-Year-Old Boy with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis. [PDF]

J Clin Med
Buzoianu O, Satirer Ö, Kuemmerle-Deschner JB, Reiser C.   +3 more
europepmc   +1 more source

Radiological changes in STING-associated vasculopathy of infancy treated with a JAK inhibitor. [PDF]

Pediatr Int
Sato T, Nagatani Y, Hirota Y, Kunitsu T, Maruo Y.   +4 more
europepmc   +1 more source

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study. [PDF]

Aliment Pharmacol Ther
Osty M, Altwegg R, Serrero M, Benezech A, Lecomte A, Cadiot G, Vuitton L, Wampach A, Nancey S, Buisson A, le Berre C, Rouillon C, Gilletta C, Goutorbe F, Fumery M, Hammoudi N, Caillo L, Vidon M, Arab N, Sickersen G, Cavicchi M, Vieujean S, Charkaoui M, Richard N, Wils P, Caron B, Amiot A, Nuzzo A, Laharie D, Kirchgesner J, Uzzan M, GETAID‐J2J group.   +31 more
europepmc   +1 more source

Successful Treatment of Cutaneous Foreign Body Granuloma with JAK Inhibitor Abrocitinib and Prednisone: A Case Report. [PDF]

Clin Cosmet Investig Dermatol
Fu J, Luo W, Wang P, Wu W, Lu J.
europepmc   +1 more source

Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis. [PDF]

J Ophthalmic Vis Res
Dominguez D, Vaclaw S, McClard CK, Jeffries MA, Noori J.   +4 more
europepmc   +1 more source

Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapy. [PDF]

JCI Insight
Huang NL, Ortega JG, Kimbrell K, Lee J, Scott LN, Peluso EM, Wang SJ, Kao EY, Kim K, Olay J, Nguyen JN, Quandt Z, Angell TE, Su MA, Lechner MG.   +14 more
europepmc   +1 more source

JAK inhibitor withdrawal causes a transient pro-inflammatory cascade: A potential mechanism for major adverse cardiac events. [PDF]

PLoS One
Gurevic I, Meudec L, Mariette X, Nocturne G, McCoy SS.   +4 more
europepmc   +1 more source

RuBi-Ruxolitinib: A Photoreleasable Antitumor JAK Inhibitor. [PDF]

J Am Chem Soc
Rafic E, Ma C, Shih BB, Miller H, Yuste R, Palomero T, Etchenique R.   +6 more
europepmc   +1 more source